Clinical trials
EBV clinical trials
Below are recruiting ebv clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06135922RecruitingPhase 1
EBV-TCR-T cells for EBV-related HLH or infection
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
Beijing, Beijing MunicipalityAges 1–60 - NCT04664179RecruitingPhase 1
EBV immune-cell treatment for EBV-positive lymphoma
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Houston, TexasAges Any age - NCT06908096RecruitingPhase 1
EBV nanoparticle vaccine study for healthy adults
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
Bethesda, MarylandAges 18–29 - NCT07438067RecruitingPhase 1
EBV-targeted cell therapy after stem cell transplant
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
BeijingAges 18–75 - NCT07450391RecruitingPhase 1/Phase 2
EBV-targeted cell therapy for EBV-related lymph disorders
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
Beijing, Beijing MunicipalityAges 18–70 - NCT07488728Recruiting
Letermovir to prevent CMV in children after stem cell transplant
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT05127980Recruiting
Study of immune antibodies after first-time EBV infection
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
BaselAges 18 years+ - NCT06119256RecruitingPhase 1
TCR-T cells for EBV after stem cell transplant
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
Beijing, Beijing MunicipalityAges 14–75 - NCT05635591Enrolling by invitationPhase 1
KSD-101 vaccine trial for EBV-related blood cancers
This early-phase trial studies KSD-101 (a vaccine treatment) for people whose blood cancers are linked to EBV and who have not responded or have relapsed after standard treatment. It may help your immune system better control the cancer, especially when other options have already been tried.
Wuhan, HubeiAges 18–70 - NCT03491605Recruiting
Follow-up study for people with high EBV virus levels
This study tracks health outcomes over time in people who have a high level of the EBV virus in their blood. It may help researchers understand what happens in chronic (long-lasting) EBV infection and which outcomes to watch for.
Wuhan, HubeiAges Any age - NCT04832607RecruitingPhase 3
Donor T-cell treatment for stubborn CMV, EBV, or Adenovirus after transplant
This Phase 3 trial tests giving special immune cells from your stem-cell donor to treat difficult-to-control viral infections after a stem cell transplant. It may help your body fight the virus when standard antiviral medicines haven’t worked well enough.
BrusselsAges 2 months+ - NCT04989491RecruitingPhase 4
Single-dose rituximab to prevent EBV after kidney transplant
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
StrasbourgAges 18 years+ - NCT06445088Recruiting
Testing a new EBV DNA test for nasopharyngeal cancer
This trial is testing a new way to diagnose nasopharyngeal cancer using a special test that looks at a change in the EBV virus DNA. It is for people who may have symptoms of this cancer or have tested positive for EBV, but have not yet been treated.
Fuzhou, FujianAges Any age - NCT07162012RecruitingEarly Phase 1
Cell therapy for EBV-positive lymphoma
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
ShanghaiAges 18–70 - NCT07368634RecruitingPhase 1/Phase 2
EBV-TCR-T cells for persistent EBV after stem cell transplant
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
BeijingAges 18–70 - NCT01555892RecruitingPhase 1
T-cell treatment for EBV-positive lymphomas
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
Houston, TexasAges Any age - NCT07381738RecruitingPhase 2
Cord blood transplant for Epstein-Barr virus diseases
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT07029958RecruitingPhase 4
Transplant protocol for EBV-related T/NK lymphoproliferative disease
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
BeijingAges birth–18 years - NCT03266653RecruitingPhase 2
T-cell therapy for stubborn Epstein-Barr virus after transplants
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT04085900Recruiting
Screening test for nasopharyngeal cancer blood markers
This study screens people in certain cities to see whether signs in the blood related to a virus (EBV) can help find nasopharyngeal cancer earlier. It may help identify higher-risk people so they can be checked sooner.
Zhongshan, GuangdongAges 30–69 - NCT05447169Recruiting
Testing blood and DNA checks for nasopharyngeal cancer risk
This study tests an Epstein-Barr virus (EBV) blood antibody and an EBV DNA test to help screen people at higher risk for nasopharyngeal cancer. It may find signs earlier in certain families where cancer runs.
Guangzhou, GuangdongAges 30–62 - NCT06789159RecruitingPhase 1
VK-2019 for relapsed/refractory EBV-positive DLBCL
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Lexington, KentuckyAges 18 years+ - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06870435Recruiting
Screening for nasopharyngeal cancer with blood tests
This study compares three different blood tests to see which works best for spotting nasopharyngeal cancer early in people at higher risk. If you live in certain areas of China, you may be able to join.
Zhuhai, GuangdongAges 30–69
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ebv?
- Yes. Clin2 currently lists 65 recruiting ebv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ebv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ebv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.